CASTLE analysis finds no benefit for once daily dosing.
D000069446:Atazanavir Sulfate; D004334:Drug Administration Schedule; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage* / Q000627:therapeutic use; D010349:Patient Compliance; D011725:Pyridines / Q000008:administration & dosage* / Q000627:therapeutic use
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate